Interim report January - December 2024
Net asset value was SEK 333.0 per share compared to SEK 257.9 at the beginning of the year, corresponding to an increase of 29.1 per cent.
Bure's net asset value was SEK 24,689M compared to SEK 19,123M at the beginning of the year.
Total return on the Bure share was 34.5 per cent; the SIX Return Index rose 8.6 per cent in the same period.
Group earnings after tax amounted to SEK 5,735M (4,749). Earnings per share were SEK 77.4 (64.0).
Interim report October - December 2024
Net asset value was SEK 333.0 per share compared to SEK 350.3 at the beginning of the quarter, corresponding to an decrease of 5.0 per cent.
Atle acquired 66 per cent of First Fondene AS in Norway and 21.6 per cent of Amaron Holding AB. Atle acquired shares in Atle Fund Management (formerly Healthinvest Partners) and increased its holding to 100 per cent. A total of SEK 171M was invested.
Events after the end of the period
Net asset value amounted to SEK 353.6 per share on February 19, 2025, corresponding to an increase of 6.2 per cent since the beginning of the year.
The Board of Directors proposes that the Annual General Meeting approves an ordinary dividend of SEK 2.75 per share (2.5).
Comments from the CEO
Strong value growth, particularly in Yubico and Mycronic, contributed to a 29.1 per cent increase in Bure's net asset value per share in 2024. SIX RX rose by 8.6 per cent. Yubico continued its strong growth during the year, increasing sales by 27 per cent. The company's share price increased 85 per cent. Mycronic reported another record year, with a 39 per cent increase in share price in 2024. Sales grew 24 per cent and operating profit exceeded SEK 2 billion for the first time. Overall, Bure's net
asset value grew by SEK 5.6 billion during 2024.
Portfolio companies Vitrolife and Xvivo finished the year strongly and reported
accelerating sales growth. Vitrolife improved its EBITDA margin to 34.0 per cent (32.3) for the full year, with business areas Consumables and Technologies posting record earnings. Commercial investments in Xvivo continued in 2024. The company reported organic sales growth of 38 per cent and made significant progress in its development projects.
Acquisition activity was slightly lower in 2024. During the summer Bure acquired 15 per cent of software company Mentimeter. The company provides SaaS platforms to improve interactivity and engagement in presentations, meetings, and training sessions. Over 150,000 customers in 200 countries use Mentimeter's digital tools.
In 2024 the company grew 19 per cent, with sales of SEK 536M. In addition to this, Atle made an investment during the autumn with its acquisition of 66 per cent of Norwegian fund company First Fondene, thereby expanding its business into the Norwegian fund market.
Last year I wrote that we were entering 2024 with a bit more optimism, and overall it was a successful year for most of the portfolio companies and for Bure as well. The start of 2025 has been strongly coloured by developments in the USA's new administration. It is difficult to see anyone gaining from the dramatic policy changes, threats of tariffs and other unforeseeable manoeuvres that have been communicated so far. Unfortunately, this creates general uncertainty about the future, which will affect equity markets and the global business landscape. I have great confidence in the portfolio companies' leaders and their ability to manage the companies to enable continued growth with good profitability.
For more information, contact
Henrik Blomquist, CEO
henrik.blomquist@bure.se
Telephone: +46 (0) 8-614 00 20
This information is information that Bure Equity AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-02-20 08:30 CET.
